123 related articles for article (PubMed ID: 7993956)
1. Attenuation of hormone responses to the 5-HT1A agonist ipsapirone by long-term treatment with fluoxetine, but not desipramine, in male rats.
Li Q; Brownfield MS; Levy AD; Battaglia G; Cabrera TM; Van de Kar LD
Biol Psychiatry; 1994 Sep; 36(5):300-8. PubMed ID: 7993956
[TBL] [Abstract][Full Text] [Related]
2. Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5-HT1A agonist, 8-OH-DPAT, in male rats.
Li Q; Levy AD; Cabrera TM; Brownfield MS; Battaglia G; Van de Kar LD
Brain Res; 1993 Dec; 630(1-2):148-56. PubMed ID: 8118681
[TBL] [Abstract][Full Text] [Related]
3. Alterations in 8-hydroxy-2-(dipropylamino)tetralin-induced neuroendocrine responses after 5,7-dihydroxytryptamine-induced denervation of serotonergic neurons.
Van de Kar LD; Li Q; Cabrera TM; Brownfield MS; Battaglia G
J Pharmacol Exp Ther; 1998 Jul; 286(1):256-62. PubMed ID: 9655867
[TBL] [Abstract][Full Text] [Related]
4. WAY-100635 inhibits 8-OH-DPAT-stimulated oxytocin, ACTH and corticosterone, but not prolactin secretion.
Vicentic A; Li Q; Battaglia G; Van de Kar LD
Eur J Pharmacol; 1998 Apr; 346(2-3):261-6. PubMed ID: 9652368
[TBL] [Abstract][Full Text] [Related]
5. Chronic treatment with an anxiolytic dose of the 5-HT1A agonist ipsapirone does not alter ipsapirone acute neuroendocrine effects.
Schmidt BH; Chaouloff F
Psychoneuroendocrinology; 1993; 18(7):457-66. PubMed ID: 7903466
[TBL] [Abstract][Full Text] [Related]
6. Long-term treatment with the antidepressants fluoxetine and desipramine potentiates endocrine responses to the serotonin agonists 6-chloro-2-[1-piperazinyl]-pyrazine (MK-212) and (+-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl (DOI).
Li Q; Brownfield MS; Battaglia G; Cabrera TM; Levy AD; Rittenhouse PA; van de Kar LD
J Pharmacol Exp Ther; 1993 Aug; 266(2):836-44. PubMed ID: 8394920
[TBL] [Abstract][Full Text] [Related]
7. Sustained desensitization of hypothalamic 5-Hydroxytryptamine1A receptors after discontinuation of fluoxetine: inhibited neuroendocrine responses to 8-hydroxy-2-(Dipropylamino)Tetralin in the absence of changes in Gi/o/z proteins.
Raap DK; Garcia F; Muma NA; Wolf WA; Battaglia G; van de Kar LD
J Pharmacol Exp Ther; 1999 Feb; 288(2):561-7. PubMed ID: 9918559
[TBL] [Abstract][Full Text] [Related]
8. Neuroendocrine responses to the serotonin2 agonist DOI are differentially modified by three 5-HT1A agonists.
Li Q; Rittenhouse PA; Levy AD; Alvarez Sanz MC; Van de Kar LD
Neuropharmacology; 1992 Oct; 31(10):983-9. PubMed ID: 1359439
[TBL] [Abstract][Full Text] [Related]
9. Blunted 5-HT1A-receptor agonist-induced corticotropin and cortisol responses after long-term ipsapirone and fluoxetine administration to healthy subjects.
Berlin I; Warot D; Legout V; Guillemant S; Schöllnhammer G; Puech AJ
Clin Pharmacol Ther; 1998 Apr; 63(4):428-36. PubMed ID: 9585797
[TBL] [Abstract][Full Text] [Related]
10. Repeated cocaine exposure inhibits the adrenocorticotropic hormone response to the serotonin releaser d-fenfluramine and the 5-HT1A agonist, 8-OH-DPAT.
Levy AD; Li Q; Van de Kar LD
Neuropharmacology; 1994; 33(3-4):335-42. PubMed ID: 7984271
[TBL] [Abstract][Full Text] [Related]
11. Chronic fluoxetine induces a gradual desensitization of 5-HT1A receptors: reductions in hypothalamic and midbrain Gi and G(o) proteins and in neuroendocrine responses to a 5-HT1A agonist.
Li Q; Muma NA; van de Kar LD
J Pharmacol Exp Ther; 1996 Nov; 279(2):1035-42. PubMed ID: 8930214
[TBL] [Abstract][Full Text] [Related]
12. Comparison of neuroendocrine and behavioral effects of ipsapirone, a 5-HT1A agonist, in three stress paradigms: immobilization, forced swim and conditioned fear.
Rittenhouse PA; Bakkum EA; O'Connor PA; Carnes M; Bethea CL; van de Kar LD
Brain Res; 1992 May; 580(1-2):205-14. PubMed ID: 1354556
[TBL] [Abstract][Full Text] [Related]
13. Neuronal circuits involved in the anxiolytic effects of the 5-HT1A receptor agonists 8-OH-DPAT ipsapirone and buspirone in the rat.
Schreiber R; De Vry J
Eur J Pharmacol; 1993 Nov; 249(3):341-51. PubMed ID: 7904566
[TBL] [Abstract][Full Text] [Related]
14. Fluoxetine-induced changes in body weight and 5-HT1A receptor-mediated hormone secretion in rats on a tryptophan-deficient diet.
D'Souza DN; Zhang Y; Garcia F; Battaglia G; Van de Kar LD
Am J Physiol Regul Integr Comp Physiol; 2004 Feb; 286(2):R390-7. PubMed ID: 14604841
[TBL] [Abstract][Full Text] [Related]
15. Subchronic treatment with anxiolytic doses of the 5-HT1A receptor agonist ipsapirone does not affect 5-HT2 receptor sensitivity in the rat.
Baudrie V; De Vry J; Broqua P; Schmidt B; Chaouloff F; Glaser T
Eur J Pharmacol; 1993 Feb; 231(3):395-406. PubMed ID: 8095465
[TBL] [Abstract][Full Text] [Related]
16. Ipsapirone and 8-OH-DPAT reduce ethanol preference in rats: involvement of presynaptic 5-HT1A receptors.
Schreiber R; Opitz K; Glaser T; De Vry J
Psychopharmacology (Berl); 1993; 112(1):100-10. PubMed ID: 7870997
[TBL] [Abstract][Full Text] [Related]
17. Characterization of the aminomethylchroman derivative BAY x 3702 as a highly potent 5-hydroxytryptamine1A receptor agonist.
De Vry J; Schohe-Loop R; Heine HG; Greuel JM; Mauler F; Schmidt B; Sommermeyer H; Glaser T
J Pharmacol Exp Ther; 1998 Mar; 284(3):1082-94. PubMed ID: 9495870
[TBL] [Abstract][Full Text] [Related]
18. 5-HT1A receptor function in normal subjects on clinical doses of fluoxetine: blunted temperature and hormone responses to ipsapirone challenge.
Lerer B; Gelfin Y; Gorfine M; Allolio B; Lesch KP; Newman ME
Neuropsychopharmacology; 1999 Jun; 20(6):628-39. PubMed ID: 10327431
[TBL] [Abstract][Full Text] [Related]
19. Role of the hypothalamic paraventricular nucleus in 5-HT1A, 5-HT2A and 5-HT2C receptor-mediated oxytocin, prolactin and ACTH/corticosterone responses.
Bagdy G
Behav Brain Res; 1996; 73(1-2):277-80. PubMed ID: 8788518
[TBL] [Abstract][Full Text] [Related]
20. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists.
Meller E; Goldstein M; Bohmaker K
Mol Pharmacol; 1990 Feb; 37(2):231-7. PubMed ID: 1968223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
